Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial
Objective Serum calprotectin appears to be an interesting biomarker associated with renal vascular disease activity in antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). The aim of this study was to assess whether serum calprotectin levels can predict decline in renal function in...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-10-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/9/4/e003477.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861129910157312 |
|---|---|
| author | Xavier Romand Benjamin Terrier Athan Baillet Philippe Gaudin Loic Guillevin Christian Pagnoux Minh Vu Chuong Marie Hélène Paclet |
| author_facet | Xavier Romand Benjamin Terrier Athan Baillet Philippe Gaudin Loic Guillevin Christian Pagnoux Minh Vu Chuong Marie Hélène Paclet |
| author_sort | Xavier Romand |
| collection | DOAJ |
| description | Objective Serum calprotectin appears to be an interesting biomarker associated with renal vascular disease activity in antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). The aim of this study was to assess whether serum calprotectin levels can predict decline in renal function in AAV patients receiving maintenance therapy.Methods Serum calprotectin levels were assessed at inclusion and month 6 in AAV patients, in complete remission after induction therapy, randomly assigned to rituximab or azathioprine. Renal function decline was defined as a 25% decrease in estimated glomerular filtration rate (eGFR) and a change in the eGFR category, or a decrease of 15 mL/min/1.73 m2. Relapse was defined as a Birmingham Vasculitis Activity Score >0 attributable to active vasculitis.Results Seventy-six AAV were included. Serum calprotectin increased from baseline to month 6 in patients with renal function decline (7940 (−226.0, 28 691) ng/ml vs −4800 (−18 777, 3708) ng/ml; p<0.001). An increase of calprotectin level was associated with a higher risk of subsequent renal function decline even after adjustment (OR 6.50 (95% CI 1.7 to 24.9) p=0.006). A significantly higher risk of relapse was observed in proteinase 3- AAV patients with an increase of serum calprotectin levels (OR 5.6 (95% CI 1.0 to 31.2), p=0.03).Conclusion An increase in serum calprotectin by month 6 compared with inclusion during remission-maintenance therapy in AAV was associated with a higher risk of renal function decline in the following 12 months.Trial registration number NCT00748644. |
| format | Article |
| id | doaj-art-af3a8dfc5f814a07a9e869d256a098ca |
| institution | Kabale University |
| issn | 2056-5933 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-af3a8dfc5f814a07a9e869d256a098ca2025-02-10T05:05:09ZengBMJ Publishing GroupRMD Open2056-59332023-10-019410.1136/rmdopen-2023-003477Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trialXavier Romand0Benjamin Terrier1Athan Baillet2Philippe Gaudin3Loic Guillevin4Christian Pagnoux5Minh Vu Chuong6Marie Hélène Paclet73 Rheumatology Department, Grenoble Alpes University Hospital, Grenoble, FranceMédecine interne, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France1 Rheumatology Department, Centre Hospitalier Universitaire Grenoble Alpes Hôpital Sud, Echirolles, FranceCNRS, UMR 5525, T-RAIG, TIMC, CHU Grenoble Alpes, Universite Grenoble Alpes, Grenoble, France1 Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France12 Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, CanadaCNRS, UMR 5525, T-RAIG, TIMC, CHU Grenoble Alpes, Universite Grenoble Alpes, Grenoble, FranceCNRS, UMR 5525, T-RAIG, TIMC, CHU Grenoble Alpes, Universite Grenoble Alpes, Grenoble, FranceObjective Serum calprotectin appears to be an interesting biomarker associated with renal vascular disease activity in antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). The aim of this study was to assess whether serum calprotectin levels can predict decline in renal function in AAV patients receiving maintenance therapy.Methods Serum calprotectin levels were assessed at inclusion and month 6 in AAV patients, in complete remission after induction therapy, randomly assigned to rituximab or azathioprine. Renal function decline was defined as a 25% decrease in estimated glomerular filtration rate (eGFR) and a change in the eGFR category, or a decrease of 15 mL/min/1.73 m2. Relapse was defined as a Birmingham Vasculitis Activity Score >0 attributable to active vasculitis.Results Seventy-six AAV were included. Serum calprotectin increased from baseline to month 6 in patients with renal function decline (7940 (−226.0, 28 691) ng/ml vs −4800 (−18 777, 3708) ng/ml; p<0.001). An increase of calprotectin level was associated with a higher risk of subsequent renal function decline even after adjustment (OR 6.50 (95% CI 1.7 to 24.9) p=0.006). A significantly higher risk of relapse was observed in proteinase 3- AAV patients with an increase of serum calprotectin levels (OR 5.6 (95% CI 1.0 to 31.2), p=0.03).Conclusion An increase in serum calprotectin by month 6 compared with inclusion during remission-maintenance therapy in AAV was associated with a higher risk of renal function decline in the following 12 months.Trial registration number NCT00748644.https://rmdopen.bmj.com/content/9/4/e003477.full |
| spellingShingle | Xavier Romand Benjamin Terrier Athan Baillet Philippe Gaudin Loic Guillevin Christian Pagnoux Minh Vu Chuong Marie Hélène Paclet Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial RMD Open |
| title | Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial |
| title_full | Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial |
| title_fullStr | Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial |
| title_full_unstemmed | Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial |
| title_short | Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial |
| title_sort | serum calprotectin and renal function decline in anca associated vasculitides a post hoc analysis of mainritsan trial |
| url | https://rmdopen.bmj.com/content/9/4/e003477.full |
| work_keys_str_mv | AT xavierromand serumcalprotectinandrenalfunctiondeclineinancaassociatedvasculitidesaposthocanalysisofmainritsantrial AT benjaminterrier serumcalprotectinandrenalfunctiondeclineinancaassociatedvasculitidesaposthocanalysisofmainritsantrial AT athanbaillet serumcalprotectinandrenalfunctiondeclineinancaassociatedvasculitidesaposthocanalysisofmainritsantrial AT philippegaudin serumcalprotectinandrenalfunctiondeclineinancaassociatedvasculitidesaposthocanalysisofmainritsantrial AT loicguillevin serumcalprotectinandrenalfunctiondeclineinancaassociatedvasculitidesaposthocanalysisofmainritsantrial AT christianpagnoux serumcalprotectinandrenalfunctiondeclineinancaassociatedvasculitidesaposthocanalysisofmainritsantrial AT minhvuchuong serumcalprotectinandrenalfunctiondeclineinancaassociatedvasculitidesaposthocanalysisofmainritsantrial AT mariehelenepaclet serumcalprotectinandrenalfunctiondeclineinancaassociatedvasculitidesaposthocanalysisofmainritsantrial |